Aducanumab
Aducanumab
Aducanumab (pronounced as ad-yoo-KAN-yoo-mab) is a monoclonal antibody medication developed for the treatment of Alzheimer's disease.
Etymology
The name "Aducanumab" is derived from the Latin roots "adu-", meaning towards, and "canumab", a suffix commonly used in the naming of monoclonal antibodies.
Usage
Aducanumab is used in the treatment of Alzheimer's disease. It is designed to target and remove beta-amyloid plaques, which are believed to contribute to the cognitive decline seen in Alzheimer's patients.
Mechanism of Action
Aducanumab is a monoclonal antibody that binds to beta-amyloid plaques in the brain. This binding triggers the immune system to remove the plaques, potentially slowing the progression of Alzheimer's disease.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Beta-amyloid plaques: Clumps of beta-amyloid protein that accumulate in the brains of people with Alzheimer's disease.
- Alzheimer's disease: A progressive brain disorder that affects memory, thinking skills, and the ability to carry out simple tasks.
See Also
- Biogen: The biotechnology company that developed Aducanumab.
- FDA: The U.S. Food and Drug Administration, which approved Aducanumab for use in 2021.
External links
- Medical encyclopedia article on Aducanumab
- Wikipedia's article - Aducanumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski